This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Essential cookies enable basic functions and are necessary for the website to function properly.
Statistics cookies collect information anonymously. This information helps us to understand how our visitors use our website.
Marketing cookies are used by third parties or publishers to display personalized advertisements. They do this by tracking visitors across websites.

Press Archive


ITM and Scil Proteins announce new Partnership for Targeted Radio Conjugates

ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical company, and Scil Proteins, the expert company in affinity ligands and targeted carriers, today announced they have entered into a partnership covering the field of targeted radio conjugates.

Under the terms of the agreement the partners plan to cover a number of programs for the discovery and development of novel targeted radio conjugates for imaging and therapy purposes, in a variety of indications. Scil Proteins will be responsible for the discovery and design of the radio conjugates based on its proprietary Affilin® platform, while ITM will use its radioisotope technology and be responsible for later-stage development and commercialization of the resulting products. The first program has commenced in the area of targeted cancer treatment.

Henning Afflerbach, CEO of Scil Proteins commented: “ITM has outstanding capabilities and deep expertise in targeted radionuclide imaging and radionuclide therapy and this collaboration reinforces our leadership in the generation of targeted carriers as homogenous products specifically tailored to imaging and therapy applications.”

“We have been impressed by the potential of Scil’s platform to deliver compounds with precisely engineered carriers”, added Steffen Schuster, CEO of ITM. “This enables us to select the compounds half-lives, short-term for imaging applications and longer-term for therapeutic applications – a perfect fit to our precision oncology strategy.”

Affilin®-based biomolecules are derived from human scaffold proteins and have high stability, affinity and specificity making them ideal for a range of applications, including those where antibodies have limitations, thus broadening the potential of biotherapeutics.

About ITM Group
ITM Isotopen Technologien München AG is a privately held group of companies dedicated to the development, production and global supply of innovative diagnostic and therapeutic radiopharmaceuticals and radionuclides. Since its foundation in 2004, ITM and its subsidiaries have established the GMP manufacturing and a robust global supply network of a novel, first-in-class medical radionuclide and -generator platform for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeting molecules and therapies in various stages of clinical development addressing a range of cancers such as neuroendocrine-, prostate- and skin cancers as well as bone metastases. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality-of-life for cancer patients while at the same time reducing side-effects and improving health economics through a new generation of targeted radionuclide therapies in precision oncology. For more information about ITM, please visit:

About Scil Proteins
Scil Proteins is a private protein engineering company that is focused on generating and optimizing affinity ligands for targeted carriers and affinity chromatography applications. Affilin®-based molecules are derived from human scaffold proteins and have high stability, affinity and specificity, making them ideal for a range of applications that demand targeting and capturing of biomolecules. The unique properties of these Affilin®-based molecules are enabling them to overcome several of the limitations of antibodies, especially in the Company’s core areas. These core areas include the development of targeted carriers for radio conjugate and drug conjugate approaches, as well as ligands for affinity chromatography of recombinant therapeutic proteins and antibodies. The Company’s activities are underpinned by state- of-the-art protein engineering technologies and a team with an unrivalled depth of expertise and track record in this area, making Scil Proteins an attractive partner. For more information about Scil Proteins, please visit: